DEF: Scilex Holding Company Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing
Proxy Statement
Scilex Holding Company is asking stockholders to approve a reverse stock split to maintain its listing on the Nasdaq Capital Market and increase the stock price.
Summary
- Scilex Holding Company is holding a special meeting of stockholders on March 19, 2025, to vote on a proposal to authorize a reverse stock split of its common stock.
- The proposed reverse stock split would be within a range of 1-for-14 to 1-for-50, without reducing the authorized number of shares.
- The Board of Directors will determine the final ratio at its sole discretion on or before March 19, 2026.
- The company received a notice from Nasdaq on November 1, 2024, indicating that its stock price had fallen below the minimum $1.00 per share requirement for continued listing.
- As of February 26, 2025, the closing price of Scilex's common stock was $0.27 per share.
- The Board believes maintaining the Nasdaq listing is important for market access and financing opportunities.
- The reverse stock split aims to increase the per-share price, but there is no guarantee it will be sustained or proportional to the split ratio.
- The Board reserves the right to abandon the reverse stock split if it's not in the company's best interest.
- Stockholders are also voting on a proposal to adjourn the meeting if necessary to solicit additional proxies.
- As of the record date, February 24, 2025, there were 243,312,885 shares of common stock and 29,057,097 shares of Series A Preferred Stock outstanding.
- Each share of common stock is entitled to one vote, while the Series A Preferred Stock is entitled to an aggregate of 32,596,371 votes.
- The reverse stock split will not change the number of authorized shares of common stock, which will remain at 740,000,000 shares.
Sentiment
Score: 5
Explanation: The document is primarily factual and procedural, outlining the reasons for and mechanics of the proposed reverse stock split. While the company expresses optimism about maintaining its Nasdaq listing, the overall tone is neutral, acknowledging both potential benefits and risks.
Positives
- Maintaining the Nasdaq listing provides a broader market for the common stock and facilitates financing and other transactions.
- A higher stock price may increase the acceptability of the common stock to a wider range of investors.
- The reverse stock split could reduce transaction costs for investors, as brokerage commissions tend to be higher for low-priced stocks.
- The increased stock price may satisfy internal policies of brokerage houses and institutional investors that prohibit or discourage investment in low-priced stocks.
Negatives
- There is no guarantee that the reverse stock split will increase the per-share price of the common stock or that the increase will be sustained.
- The reverse stock split may be viewed negatively by the market and could lead to a decrease in the company's overall market capitalization.
- Some stockholders may own fewer than one hundred shares after the reverse stock split, leading to incrementally higher trading costs.
- The reverse stock split may decrease, or may not increase, the liquidity of the common stock due to the reduced number of outstanding shares.
Risks
- If the reverse stock split is not approved, the company may be delisted from the Nasdaq Capital Market.
- Delisting could adversely affect the liquidity of the common stock and make it less convenient for investors to buy or sell shares.
- Delisting could harm the company's ability to raise capital and may result in a loss of confidence by investors, suppliers, customers, and employees.
- The effect of the reverse stock split on the market prices for the common stock cannot be accurately predicted.
- The reverse stock split may have an anti-takeover effect by increasing the proportion of unissued authorized shares to issued shares.
Future Outlook
The company aims to regain compliance with Nasdaq listing requirements and believes the reverse stock split is a potential means to achieve this. The Board will determine whether to proceed with the reverse stock split based on market conditions and other factors.
Management Comments
- The Board believes that maintaining our listing on the Nasdaq Capital Market provides a broader market for the Common Stock and facilitates the use of the Common Stock in financing and other transactions.
- We expect the Reverse Stock Split, if effected, to facilitate the continuation of such listing.
Industry Context
Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. Other companies in similar situations may consider this option to maintain listing and attract investors.
Comparison to Industry Standards
- Many companies facing Nasdaq delisting due to the minimum bid price rule have implemented reverse stock splits.
- Comparable companies that have used reverse stock splits include those in the biotechnology and pharmaceutical sectors facing similar market pressures.
- The success of a reverse stock split in maintaining listing and increasing stock price varies depending on company-specific factors and overall market conditions.
- The range of 1-for-14 to 1-for-50 is within the typical range seen in similar situations, but the specific ratio chosen will depend on Scilex's particular circumstances.
Stakeholder Impact
- The reverse stock split could impact stockholders by changing the number of shares they own and potentially affecting the market price of the stock.
- Employees may be affected by the company's ability to maintain its Nasdaq listing and raise capital.
- Customers and suppliers may be affected by the company's financial stability and access to resources.
Next Steps
- Stockholders will vote on the reverse stock split proposal at the Special Meeting on March 19, 2025.
- If approved, the Board of Directors will determine the final reverse stock split ratio and the timing of implementation.
- The company will notify stockholders of the effective date of the reverse stock split and provide instructions for exchanging stock certificates.
Key Dates
| Date | Description |
|---|---|
| November 9, 2022 | Date of filing of the original Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware. |
| November 10, 2022 | Date of filing of Certificate of Designations of Series A Preferred Stock with the Delaware Secretary of State. |
| January 6, 2021 | Date of the Public Warrant Agreement between Scilex and Continental Stock Transfer & Trust Company. |
| November 1, 2024 | Date Scilex received notice from Nasdaq regarding non-compliance with minimum bid price requirement. |
| November 12, 2024 | Deadline for stockholder proposals for inclusion in the 2025 annual meeting proxy statement. |
| December 6, 2024 | Earliest date for stockholder notice of proposals for the 2025 annual meeting (not for inclusion in proxy statement). |
| December 11, 2024 | Date of the Securities Purchase Agreement among the Company and the investors named therein. |
| January 6, 2025 | Latest date for stockholder notice of proposals for the 2025 annual meeting (not for inclusion in proxy statement). |
| January 17, 2025 | Date Oramed Pharmaceuticals Inc. filed a statement on Schedule 13G with the SEC. |
| January 31, 2025 | Date for beneficial ownership information in the proxy statement. |
| February 4, 2025 | Deadline for notices of a solicitation of proxies in support of director nominees other than Scilex's own nominees. |
| February 24, 2025 | Record date for the Special Meeting. |
| February 26, 2025 | Closing price of common stock was $0.27 per share. |
| February 27, 2025 | Date of the proxy statement. |
| March 3, 2025 | Expected date of mailing the proxy statement and proxy card to stockholders. |
| March 12, 2024 | Date of filing of the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2023, with the SEC. |
| March 18, 2025 | Deadline to vote by Internet or phone. |
| March 19, 2025 | Date of the Special Meeting of Stockholders. |
| April 5, 2024 | Date of the 2024 annual meeting of stockholders. |
| April 30, 2025 | Initial deadline to regain compliance with Nasdaq's minimum bid price requirement. |
| March 19, 2026 | Deadline for the Board to determine the final reverse stock split ratio or abandon the plan. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.